Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020

Although mortality from cardiovascular disease (CVD) has declined consistently in the United States, CVD remains a major public health burden for Black US residents.^1,2 Given that clinical trials provide the foundational evidence that helps shape guideline recommendations for physicians and support approval of new drugs by the US Food and Drug Administration (FDA), equitable representation of Black US residents in clinical trials is vitally important. Therefore, this study was designed to investigate the representation status of Black US residents in crucial clinical trials supporting FDA approval of cardiovascular drugs.